샘플 요청 목록

 카트 문의
시장보고서
상품코드
1873211

세계의 체외 대장암 스크리닝 검사 시장

In-Vitro Colorectal Cancer Screening Tests
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 체외 대장암 스크리닝 검사 시장은 2030년까지 11억 달러에 달할 전망

2024년에 9억 2,980만 달러로 추정되는 세계의 체외 대장암 스크리닝 검사 시장은 2024-2030년의 분석 기간에 CAGR 3.3%로 성장하며, 2030년까지 11억 달러에 달할 것으로 예상됩니다. 이 리포트에서 분석 대상이 된 부문의 하나인 변잠혈 검사는 3.8%의 CAGR을 기록하며, 분석 기간 종료시까지 8억 8,150만 달러에 달할 것으로 예측됩니다. 바이오마커 검사 부문의 성장률은 분석 기간에 1.5%의 CAGR로 추정되고 있습니다.

미국 시장은 2억 4,820만 달러로 추정되는 한편, 중국은 5.9%의 CAGR로 성장할 것으로 예측됩니다.

미국의 체외 대장암 스크리닝 검사 시장은 2024년에 2억 4,820만 달러로 추정되고 있습니다. 세계 2위의 경제 규모를 자랑하는 중국 시장은 2024-2030년의 분석 기간에 CAGR 5.9%로 추이하며, 2030년까지 2억 3,340만 달러 규모에 달할 것으로 예측되고 있습니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다를 들 수 있으며, 분석 기간 중 각각 0.5%, 4.1%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 1.4%의 CAGR로 성장할 것으로 예측됩니다.

세계의 대장암 스크리닝 검사(체외진단) 시장 - 주요 동향과 촉진요인 요약

체외 대장암 선별검사는 무엇이며, 왜 중요한가?

체외 대장암 스크리닝 검사는 혈액, 대변, 기타 생체 시료 등 비침습적 검체를 통해 대장암 또는 그 전조 병변의 존재를 검출하는 진단 툴입니다. 이 검사들은 대장이나 직장에 암세포나 전암세포가 존재한다는 것을 나타낼 수 있는 DNA 돌연변이, 혈액 흔적, 비정상적인 단백질 수치와 같은 특정 바이오마커를 식별하기 위해 고안되었습니다. 대장암은 전 세계에서 가장 흔하고 치명적인 암 중 하나이기 때문에 조기 발견이 환자의 예후를 개선하는 데 매우 중요합니다. 체외 검사는 환자에게 위협적이거나 불편하게 느껴지는 기존의 대장 내시경 검사에 비해 덜 침습적이고 접근성이 좋은 대안을 제공합니다. 이러한 검사가 치료가 가장 효과적인 초기 단계에서 암을 발견할 수 있는 능력은 사망률을 낮추고 위험에 처한 환자의 장기 생존율을 향상시키는 데 중요한 툴이 되고 있습니다.

체외 대장암 스크리닝 검사는 조기 발견에 있으며, 어떻게 상황을 바꾸고 있는가?

체외 대장암 스크리닝 검사는 보다 간편하고 환자에게 부담이 적은 검사 방법을 제공함으로써 암 조기 발견에 대한 접근 방식에 혁명을 일으키고 있습니다. 내시경 검사 등 기존 방법은 효과가 높지만, 침습적인 특성으로 인해 환자들의 저항에 부딪히는 경우가 많았습니다. 이에 비해 혈액이나 대변 샘플을 분석하여 암 징후를 검사하는 체외 검사는 침습성이 훨씬 낮고, 집에서 할 수 있는 경우가 많아 검진 순응도와 수검률을 높이고 있습니다. 대변잠혈검사(FIT), 대변 DNA 검사, 혈액검사 등의 검사는 검진 과정을 간소화하여 정기적인 대장내시경 검사를 받을 의지와 능력이 없는 사람들도 쉽게 접근할 수 있도록 하고 있습니다. 이러한 검사는 대장암 가족력이 있거나 50세 이상 등 정기적인 검진이 필요한 고위험군에게 특히 중요합니다. 검사의 편의성 향상으로 체외검사는 증상이 나타나기 전 가장 초기에 암을 발견하는 데 기여하고 있습니다. 이를 통해 치료 성공률을 높일 수 있을 뿐만 아니라, 조기 발견으로 침습적인 시술의 필요성을 줄여 의료비 부담도 줄일 수 있습니다. 이러한 발전으로 환자 치료는 보다 예방적이고 선제적으로 변화하고 있으며, 의료 전문가들이 대장암에 대해 보다 효과적이고 능동적으로 대처할 수 있게 되었습니다.

대장암 체외 검진을 형성하는 기술 혁신은 무엇인가?

체외 대장암 스크리닝 분야는 특히 바이오마커 검출, 분자진단, 자동화 분야에서 기술적으로 큰 진전을 보이고 있습니다. 주요 발전 중 하나는 차세대 염기서열 분석(NGS) 기술의 활용으로 대장암과 관련된 유전자 변이 및 DNA 변화를 상세하게 분석할 수 있게 되었습니다는 점입니다. NGS는 여러 유전자 마커를 동시에 검출할 수 있으며, 스크리닝 검사의 정확성과 신뢰성을 높이고 있습니다. 또한 혈액내 순환 종양 DNA(ctDNA)를 분석하는 액체생검 기술은 암 조기 발견을 위한 강력한 툴로 부상하고 있으며, 모니터링 및 스크리닝을 위한 최소 침습적 옵션을 제공합니다. 인공지능(AI)과 머신러닝도 체외검사의 민감도와 특이성을 향상시키는 데 중요한 역할을 하고 있습니다. AI 기반 알고리즘은 대규모 데이터세트를 분석하여 바이오마커 수준의 패턴을 식별함으로써 암 검출의 정확도를 높이고 위양성 및 위음성을 최소화합니다. 이를 통해 스크리닝 프로세스를 정교화하여 환자가 적시에 정확한 진단을 받을 수 있도록 보장합니다. 또한 자동화의 발전으로 이러한 검사의 효율성과 확장성이 향상되어 분석에 필요한 비용과 시간을 절감할 수 있습니다. 이는 의료시스템이 대장암 검진 보급을 위한 접근성 향상과 비용 효율성 향상을 목표로 하고 있는 상황에서 특히 중요한 의미를 갖습니다.

체외 대장암 검진 시장의 빠른 성장을 이끄는 요인은 무엇인가?

체외 대장암 검진 시장의 성장은 조기 발견에 대한 인식 증가, 검진 기술의 발전, 대장암 유병률 증가 등 여러 요인에 의해 주도되고 있습니다. 공중보건 캠페인이 정기적인 암 검진의 중요성, 특히 고위험군 검진의 중요성을 강조하면서 비침습적이고 접근성이 좋은 검사법에 대한 수요가 급증하고 있습니다. 대장내시경과 같은 기존 검진에 비해 환자들에게 부담이 적은 체외검사는 편리성, 저렴한 비용, 불편함의 감소로 보급이 확대되어 정기적인 검진 수검을 촉진하고 있습니다. 기술 혁신도 주요 촉진요인입니다. 분자진단, 바이오마커 발견, 액체생검 기술의 혁신으로 체외 검사의 민감도와 특이도가 크게 향상되어 정확성과 신뢰성이 향상되고 있습니다. 이를 통해 기존 방식에 의존하던 의료진과 환자들을 끌어들이며 시장이 확대되고 있습니다. 또한 전 세계에서 고령화와 대장암 발병률 증가로 인해 효과적인 조기 발견 솔루션에 대한 수요가 증가하고 있습니다. 대장암 고위험 연령층에 속하는 사람들이 늘어남에 따라 접근이 용이하고 비침습적인 검진 툴의 필요성이 계속 증가하고 있습니다. 또한 신흥 시장에서의 규제적 지원과 의료 인프라의 확충은 시장 성장을 더욱 촉진하고 있습니다. 정부와 의료기관은 국가검진 프로그램의 일환으로 체외 대장암 검진을 권장하는 경향이 강화되고 있으며, 다양한 지역에서 도입을 장려하고 있습니다. 이러한 요인들이 결합하여 체외 대장암 검진 시장을 발전시키고 대장암과의 싸움에서 조기 발견율을 향상시켜 환자의 치료 결과를 개선하는 데 기여하고 있습니다.

부문:

부문(변잠혈 검사, 바이오마커 검사, CRC DNA 스크리닝 검사), 최종 사용(병원, 임상 진단 검사실, 기타 최종 사용)

조사 대상 기업의 예

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

AI 통합

검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석 방식을 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM이나 산업 전문 SLM에 대한 쿼리 방식에 의존하는 대신, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.

관세 영향 계수

이번 보고서에는 Global Industry Analysts가 예측한 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따른 기업의 경쟁력 변화에 따라 지역 시장에 미치는 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학을 통해 경쟁사들에게 영향을 미칠 것입니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.11.26

Global In-Vitro Colorectal Cancer Screening Tests Market to Reach US$1.1 Billion by 2030

The global market for In-Vitro Colorectal Cancer Screening Tests estimated at US$929.8 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$881.5 Million by the end of the analysis period. Growth in the Biomarker Test segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$248.2 Million While China is Forecast to Grow at 5.9% CAGR

The In-Vitro Colorectal Cancer Screening Tests market in the U.S. is estimated at US$248.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$233.4 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global In-Vitro Colorectal Cancer Screening Tests Market - Key Trends and Drivers Summarized

What Are In-Vitro Colorectal Cancer Screening Tests and Why Are They Vital?

In-vitro colorectal cancer screening tests are diagnostic tools used to detect the presence of colorectal cancer or its precursors through non-invasive samples such as blood, stool, or other biological specimens. These tests are designed to identify specific biomarkers, such as DNA mutations, blood traces, or abnormal protein levels, which may indicate the presence of cancerous or pre-cancerous cells in the colon or rectum. As colorectal cancer remains one of the most common and deadly cancers worldwide, early detection is critical to improving patient outcomes. In-vitro screening offers a less invasive, more accessible alternative to traditional colonoscopy, which can often be intimidating or uncomfortable for patients. The ability of these tests to detect cancer at an early stage-when treatment is most effective-makes them a crucial tool in reducing mortality rates and improving long-term survival for patients at risk.

How Are In-Vitro Colorectal Cancer Screening Tests Changing the Game in Early Detection?

In-vitro colorectal cancer screening tests are revolutionizing the approach to early cancer detection by providing easier, more patient-friendly methods of screening. Traditional methods, such as colonoscopy, although highly effective, have often faced resistance from patients due to the invasive nature of the procedure. In contrast, in-vitro tests, which involve analyzing blood or stool samples for signs of cancer, are much less invasive and can often be conducted in the comfort of a patient’s home, enhancing compliance and screening rates. Tests like fecal immunochemical tests (FIT), stool DNA tests, and blood-based assays have simplified the screening process, making it more accessible to populations that are either unwilling or unable to undergo routine colonoscopies. These tests are especially significant for high-risk groups, including those with a family history of colorectal cancer or individuals over the age of 50, who require regular screening. By increasing the ease of screening, in-vitro tests are helping to identify cancer at its earliest stages, before symptoms appear. This not only improves the chances of successful treatment but also lowers the healthcare burden by reducing the need for more invasive procedures when the disease is caught early. With these advancements, patient care is becoming more preventive and less reactive, enabling medical professionals to address colorectal cancer more effectively and proactively.

What Technological Breakthroughs Are Shaping In-Vitro Colorectal Cancer Screening?

The field of in-vitro colorectal cancer screening has seen significant advancements in technology, particularly in the areas of biomarker detection, molecular diagnostics, and automation. One major development is the use of next-generation sequencing (NGS) technology, which enables the detailed analysis of genetic mutations and DNA alterations associated with colorectal cancer. NGS allows for the detection of multiple genetic markers simultaneously, increasing the accuracy and reliability of screening tests. Additionally, liquid biopsy technologies, which analyze circulating tumor DNA (ctDNA) in the bloodstream, are emerging as a powerful tool for early cancer detection, offering a minimally invasive option for monitoring and screening. Artificial intelligence (AI) and machine learning are also playing a critical role in improving the sensitivity and specificity of in-vitro tests. By analyzing large datasets and identifying patterns in biomarker levels, AI-powered algorithms can enhance the precision of cancer detection, minimizing false positives and negatives. This helps in refining the screening process and ensures that patients receive timely and accurate diagnoses. Furthermore, advancements in automation are making these tests more efficient and scalable, reducing the cost and time required for analysis. This is particularly important as healthcare systems strive to make colorectal cancer screening more accessible and cost-effective for widespread use.

What Is Driving the Rapid Growth of the In-Vitro Colorectal Cancer Screening Market?

The growth in the in-vitro colorectal cancer screening market is driven by several factors, including increasing awareness of early detection, advancements in screening technology, and the rising prevalence of colorectal cancer. As public health campaigns emphasize the importance of regular cancer screening, particularly for high-risk individuals, demand for non-invasive and accessible testing methods is surging. In-vitro tests, which provide a more patient-friendly alternative to traditional screening procedures like colonoscopy, are gaining popularity due to their convenience, lower cost, and reduced discomfort, encouraging more people to undergo regular screening. Technological advancements are another key driver. Innovations in molecular diagnostics, biomarker discovery, and liquid biopsy technologies are significantly enhancing the sensitivity and specificity of in-vitro tests, making them more accurate and reliable. This is expanding the market by attracting healthcare providers and patients who previously relied on traditional methods. Additionally, the aging global population, coupled with the increasing incidence of colorectal cancer, is fueling demand for effective early detection solutions. As more people fall into the high-risk age bracket for colorectal cancer, the need for accessible and non-invasive screening tools continues to grow. Moreover, regulatory support and expanding healthcare infrastructure in emerging markets are further contributing to the market’s growth. Governments and healthcare organizations are increasingly endorsing in-vitro colorectal cancer screening as part of national screening programs, driving adoption across various regions. Together, these factors are propelling the in-vitro colorectal cancer screening market forward, helping to improve early detection rates and, ultimately, patient outcomes in the fight against colorectal cancer.

SCOPE OF STUDY:

The report analyzes the In-Vitro Colorectal Cancer Screening Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Fecal Occult Blood Test, Biomarker Test, CRC DNA Screening Test); End-Use (Hospitals, Clinical Diagnostic Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • In-Vitro Colorectal Cancer Screening Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Colorectal Cancer Propels Growth in In-Vitro Screening Test Demand
    • Technological Advancements in Biomarker Detection Strengthen Business Case for Early Diagnosis
    • Shift Towards Non-invasive Diagnostic Techniques Expands Addressable Market for In-Vitro Colorectal Cancer Tests
    • Aging Population Spurs Growth of Colorectal Cancer Screening, Driving Demand for Advanced In-Vitro Diagnostics
    • Increased Consumer Preference for At-home Testing Solutions Generates Demand for Convenient Screening Options
    • Advances in Molecular Diagnostics Throws the Spotlight on Personalized Medicine and Targeted Screening
    • Rising Adoption of Liquid Biopsy Techniques Propels Innovation and Expansion in Screening Solutions
    • Increased Integration of AI and Machine Learning in Diagnostic Tools Drives Accuracy in Test Outcomes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World In-Vitro Colorectal Cancer Screening Tests Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Fecal Occult Blood Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Biomarker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for CRC DNA Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제